Starling Oncology, Inc. (STLN)

Starling Oncology Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	30.28	33.57	49.67	33.49	14.01	114.3
Short-Term Investments	-	-	-	49.37	59.8	-
Cash & Short-Term Investments	30.28	33.57	49.67	82.86	73.81	114.3
Cash Growth	-23.80%	-32.42%	-40.05%	12.26%	-35.43%	1805.62%
Accounts Receivable	58.13	59	48.34	42.36	39.82	20.01
Other Receivables	1.32	0.32	0.35	0.55	0.62	1.24
Receivables	59.45	59.32	48.68	42.91	40.43	21.24
Inventory	24.29	16.88	10.04	13.68	9.26	6.44
Prepaid Expenses	2.84	2.99	4.03	4.05	6.92	11.2
Restricted Cash	-	-	-	-	-	0.88
Total Current Assets	116.86	112.75	112.42	143.49	130.42	154.06
Property, Plant & Equipment	33.22	33.06	37.67	40.05	33.04	4.19
Long-Term Investments	-	-	-	-	58.35	-
Goodwill	7.23	7.23	7.23	7.23	21.42	26.63
Other Intangible Assets	10.3	11.02	14.81	17.9	17.96	18.25
Other Long-Term Assets	0.62	0.61	0.59	0.56	0.48	0.32
Total Assets	168.23	164.66	172.72	209.24	261.67	203.44

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	47.65	43.17	24.32	14.43	9.37	15.56
Accrued Expenses	17.62	12.3	10.05	10.7	9.42	8.33
Current Portion of Long-Term Debt	-	-	-	-	-	0.18
Current Portion of Leases	7.44	7.19	6.8	6.36	5.5	-
Current Income Taxes Payable	-	-	-	-	0.26	0.13
Current Unearned Revenue	-	2.28	2.35	1.09	1.14	0.26
Other Current Liabilities	6.64	6.02	8.69	2.21	4.04	5.33
Total Current Liabilities	79.35	70.96	52.22	34.79	29.72	29.8
Long-Term Debt	78.61	77.4	93.13	86.83	80.62	-
Long-Term Leases	18.86	19.16	23.22	26.49	22.06	-
Long-Term Deferred Tax Liabilities	-	-	0.03	0.03	0.11	0.37
Other Long-Term Liabilities	7.69	12.86	0.53	4.08	5.98	69.11
Total Liabilities	184.52	180.38	169.13	152.22	138.49	99.28

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	0.01	0.01	0.01	0.01	0.01	0.01
Additional Paid-In Capital	258.64	256.71	215.41	204.19	186.25	167.39
Retained Earnings	-273.91	-271.42	-210.81	-146.15	-63.08	-63.23
Treasury Stock	-1.02	-1.02	-1.02	-1.02	-	-
Total Common Equity	-16.29	-15.72	3.59	57.03	123.18	104.16
Shareholders' Equity	-16.29	-15.72	3.59	57.03	123.18	104.16
Total Liabilities & Equity	168.23	164.66	172.72	209.24	261.67	203.44

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	104.91	103.75	123.15	119.68	108.18	0.18
Net Cash (Debt)	-74.63	-70.19	-73.48	-36.82	-34.37	114.12
Net Cash Growth	-	-	-	-	-	-
Net Cash Per Share	-0.76	-0.76	-0.98	-0.50	-0.43	1.72
Filing Date Shares Outstanding	99.98	98.84	75.75	74.31	74.55	73.25
Total Common Shares Outstanding	99.97	98.86	75.74	74.15	73.27	73.25
Working Capital	37.51	41.79	60.2	108.71	100.7	124.26
Book Value Per Share	-0.16	-0.16	0.05	0.77	1.68	1.42
Tangible Book Value	-33.82	-33.97	-18.45	31.89	83.8	59.29
Tangible Book Value Per Share	-0.34	-0.34	-0.24	0.43	1.14	0.81
Machinery	8.62	7.42	6.05	5.84	3.88	2.11
Construction In Progress	0.44	1.14	0.11	1.8	1.14	0.52
Leasehold Improvements	13.26	12.85	12.5	9.21	6.66	3.39

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 4, 2026

Data Sources Report a data error